Fortuna Fix
Reprogram and regenerate. A revolution in medicine.
Reprogram and regenerate. A revolution in medicine.
Fortuna Fix is a pioneering regenerative medicine company with a focus on neuronal repair and regeneration. Founded in 2015 and headquartered in the United Kingdom, the company's mission is to redefine healthcare through regenerative medicine, addressing conditions that cannot be cured by traditional therapies. Fortuna Fix stands out in the field for its development of ethical regenerative medicine solutions that can restore functionality in patients following neurotrauma and neurodegeneration. Their patented technology portfolio includes autologous neural precursor cells (drNPC™) produced by direct reprogramming and Regeneration Matrix™ (RMx™) implants. Furthermore, their automated manufacturing process for drNPC™ enables rapid scale-up and production. The company successfully secured a significant $25.00M Series B investment on 08 November 2017 with support from Amgen Ventures and Salamander Invest AS. Fortuna Fix's revolutionary approach to regenerative medicine positions them as a key player in the biotechnology and pharmaceutical industries, striving to bring about a healthcare revolution.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $25.00M | 2 |
|
08 Nov 2017 |
No recent news or press coverage available for Fortuna Fix.
We care about your data, and we'd love to use cookies make your experience better.